BERGEN, Norway, Jan. 7, 2025 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing the novel, selective AXL kinase inhibitor bemcentinib for lung cancer announced today that the first patient has been included in a clinical trial sponsored by the Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio). The study is led by Josephine A. Taverna, MD, a thoracic oncologist at the Mays Cancer Center and Associate Professor in the Division of Hematology and Oncology at UT Health San Antonio.

"Dr. Taverna's research has shown that AXL and JAK-STAT3 work in tandem to transmit signals promoting tumor growth and metastasis in advanced lung cancer. We are pleased to see this research advancing into clinical application and believe this study aligns closely with BerGenBio's strategic focus on addressing the significant unmet needs of lung cancer patients, including first-line Non-Small Cell Lung Cancer patients with mutations in the STK11 gene," said Olav Hellebø, Chief Executive Officer of BerGenBio.

The trial is designed to study BerGenBio's bemcentinib in combination with pacritinib, which is a JAK2 inhibitor indicated for treatment of the bone marrow disorder myelofibrosis in patients with platelet counts below 50 x 10⁹/L. It works by blocking certain growth factors and cytokines. Pacritinib is marketed in the United States as VONJO^® and owned by Swedish Orphan Biovitrum AB (Sobi^®) (STO: SOBI), a specialized international biopharmaceutical company. Bemcentinib is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase, a promising therapeutic target for serious diseases.

The study will include patients with lung adenocarcinoma, the most common type of lung cancer in the United States, accounting for approximately 40% of all lung cancers. The study is funded by a grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH).

Contacts

Olav Hellebø, CEO, BerGenBio ASA
ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

About the Trial (NCT 06516887)

The trial sponsored by the Mays Cancer Center at The University of Texas Health Science Center at San Antonio is entitled "Study of Bemcentinib plus Pacritinib in Patients with Advanced adenocarcinoma" is a Phase Ib/II, open-label, single institution dose-escalation, safety, pharmacokinetics, pharmacodynamic and efficacy study. It is anticipated that a total of 44 patients will be enrolled in the trial. In the PhIb portion varying doses of bemcentinib and pacritinib will be studied in combination to determine safety, tolerability and the maximum tolerated dose. The Phase II portion of the trial will study the dose(s) selected in Phase Ib and will assess the overall response rate and progression free survival of treated patients.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bergenbio-asa/r/bergenbio-announces-first-patient-entered-into-advanced-adenocarcinoma-lung-cancer-trial,c4088137

View original content:https://www.prnewswire.co.uk/news-releases/bergenbio-announces-first-patient-entered-into-advanced-adenocarcinoma-lung-cancer-trial-302343911.html

Tags

More Like This

BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi®

BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation

BerGenBio Reports Third Quarter 2023 Financial Results

BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients

BerGenBio Announces Selection of 2nd Dose in Phase 2a First Line STK11m Non-Small Lung Cancer Trial

New Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting

BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m Non-Small Cell Lung Cancer

BerGenBio Announces Poster Presentation at Upcoming SITC Meeting